Intravenous Ondansetron Dosing for a 15 kg Child
For a 15 kg child, administer ondansetron 0.15 mg/kg intravenously (2.25 mg), diluted in 10-50 mL of normal saline or 5% dextrose, infused over 15 minutes.
Context-Specific Dosing
The appropriate dose depends on the clinical indication:
For Chemotherapy-Induced Nausea and Vomiting (CINV)
- Dose: 0.15 mg/kg IV (2.25 mg for a 15 kg child)
- Administration: Dilute in 10-50 mL of compatible fluid and infuse over 15 minutes 1
- Timing: Begin 30 minutes before chemotherapy, then repeat at 4 and 8 hours after the first dose (total of 3 doses) 1
- Maximum per dose: 16 mg 1
This weight-based dosing is FDA-approved for children ≥6 months of age receiving emetogenic chemotherapy 1. The dilution requirement is critical for this indication—never administer undiluted for CINV prophylaxis 1.
For Postoperative Nausea and Vomiting (PONV)
- Dose: 0.1 mg/kg IV (1.5 mg for a 15 kg child)
- Administration: Can be given undiluted over 2-5 minutes 1
- Timing: Single dose administered immediately before or during anesthesia induction 1
For PONV, the FDA label specifies 0.1 mg/kg for children weighing ≤40 kg 1. Dilution is not required for PONV prophylaxis, which distinguishes it from CINV dosing 1.
Evidence-Based Considerations
Dose-Response Data
Multiple pediatric studies demonstrate that lower doses are equally effective for PONV:
- 0.05 mg/kg was as effective as 0.1 mg/kg and 0.15 mg/kg in preventing postoperative emesis 2, 3
- However, one study found 0.15 mg/kg (150 mcg/kg) superior to 0.05 mg/kg (50 mcg/kg) specifically for tonsillectomy 4
Clinical Pearl: Despite research suggesting lower doses may suffice, the FDA-approved dose of 0.1 mg/kg for PONV represents the regulatory standard and should be followed in routine practice 1.
Treatment of Established Vomiting
If the child is already vomiting postoperatively:
- Dose: 0.1 mg/kg IV (up to 4 mg maximum) 5
- This was 78% effective in stopping further emesis within 2 hours versus 34% for placebo 5
- Median time to discharge was significantly shorter (153 vs 173 minutes) 5
Critical Safety Points
Dilution Requirements
- CINV: Mandatory dilution in 10-50 mL for children ≤10 kg or ≤1 year; 50 mL for older children 1
- PONV: Dilution not required 1
- Never mix with alkaline solutions—precipitation may occur 1
QTc Prolongation Risk
While ondansetron can prolong QTc interval, no QTc prolongation was observed in a recent pediatric study using both single and divided dosing strategies 6. However, caution is warranted in children with:
- Congenital long QT syndrome
- Electrolyte abnormalities (hypokalemia, hypomagnesemia)
- Concurrent QT-prolonging medications
Hepatic Impairment
In severe hepatic impairment (Child-Pugh ≥10), maximum daily dose is 8 mg total 1. This is unlikely to apply to most pediatric patients but should be considered in children with known liver disease.
Common Pitfalls to Avoid
Using CINV dosing for PONV: The 0.15 mg/kg dose is specifically for chemotherapy-related nausea; PONV requires only 0.1 mg/kg 1
Forgetting dilution for CINV: Undiluted administration is only appropriate for PONV 1
Exceeding maximum doses: Even with weight-based dosing, never exceed 16 mg per dose for CINV or 4 mg for PONV in children ≤40 kg 1
Inappropriate use in gastroenteritis: Recent evidence from Pakistan shows ondansetron reduces vomiting in dehydrated children 7 but provides no benefit in non-dehydrated children with gastroenteritis 8
Practical Administration
For a 15 kg child:
- CINV: Draw up 2.25 mg (from 2 mg/mL vial = 1.125 mL), dilute in 50 mL NS or D5W, infuse over 15 minutes
- PONV: Draw up 1.5 mg (0.75 mL), may give undiluted IV push over 2-5 minutes
The medication is compatible with normal saline, 5% dextrose, and combinations thereof, remaining stable for 48 hours at room temperature after dilution 1.